Silver Book Fact

Since 1980, 83 percent of gains in life expectancy for cancer patients have been attributable to new treatments.

Sun E, Lakdawall D, Ryes C, Goldman D, et al. The Determinants of Recent Gains in Cancer Survival: An analysis of the Surveillance, Epidemiology, and End Results (SEER) database. J Clin Oncolo. 2008; 27(15S). http://ascopubs.org/doi/abs/10.1200/jco.2008.26.15_suppl.6616

Reference

Title
The Determinants of Recent Gains in Cancer Survival: An analysis of the Surveillance, Epidemiology, and End Results (SEER) database
Publication
J Clin Oncolo
Publication Date
2008
Authors
Sun E, Lakdawall D, Ryes C, Goldman D, et al
Volume & Issue
Volume 27, Issue 15S
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Human Value

Related Facts

  • The use of imatinib (Gleevec) has increased the eight-year survival rate for early chronic-phase myelogenous leukemia from 65% to 84%.  
  • According to the Pharmaceutical Research and Manufacturers of America, a medicine in development targets late-stage metastatic melanoma. The medicine contains a gene encoding antigen that may be able to…  
  • The 1-year survival rate for lung cancer has increased from 37% in 1975 to 42% in 1999-2001, largely because of improvements to surgical techniques and with combined therapies.  
  • There are nearly 14.5 million people in the U.S. living with a history of cancer.  
  • Investments in cancer research and development between 1998 and 2000 has generated 23 million additional healthy years of life and $1.9 trillion of additional social value.